Syncom Formulation India Ltd. is a pharmaceutical company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Indore, Madhya Pradesh and currently employs 799 full-time employees.  The firm is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. The company is also engaged in the renting of properties. The company manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The firm's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.

Syncom Formulations Dividends

524470.BO dividend metrics

Dividend per share

524470.BO dividend history